Aptevo raises $4.5M through warrant exercise and PIPE
What's the deal? Aptevo TherapeuticsDealroom has a profile for this one. Try Dealroom → (NASDAQ: APVO), a Seattle-based clinical-stage biotechnology company, said on August 12, 2026 it expects to raise approximately $4.5 million in gross proceeds through a warrant inducement and a concurrent private placement. Roth Capital PartnersDealroom has a profile for this one. Try Dealroom → is acting as exclusive placement agent.
How it's structured: Existing warrant holders agreed to exercise warrants for 254,922 shares at a reduced price of $4.03 each. Separately, Aptevo agreed to sell up to 861,708 shares in a private placement at $4.03 per share, alongside new warrants.
Why now? Aptevo develops multispecific immuno-oncology therapeutics, a capital-intensive field where clinical-stage companies routinely tap public and private markets to fund operations. The company intends to use net proceeds for working capital.
What's the endgame? The deal issues fresh warrants — up to 1,274,610 inducement warrants and 4,308,540 common warrants — most exercisable only after Aptevo obtains stockholder approval and expiring five years later. That structure gives Aptevo a path to further capital if its share price supports future exercises.
The transactions are expected to close on or about August 13, 2026, subject to customary conditions.
The signal: At $4.5 million, this is a small raise, sitting near the bottom of the funding-size distribution. For cash-constrained clinical-stage biotechs, warrant inducements paired with PIPEs remain a familiar route to shore up working capital without a large dilutive offering.
Read more: Access Newswire
Image credit: Generated with Gemini
